低分子化合物によるEPAS1誘導性IL-31産生の選択的阻害

1. Weidinger S, Beck LA, Beiber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018;4:1.

2. Topal FA, Zuberbier T, Makris MP, Hofmann M. The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Curr Opin Allergy Clin Immunol 2020;20:367-73.

3. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin infiammation. J Allergy Clin Immunol 2006;117:411-7.

4. Bilsborough J, Leung DYM, Maurer M, Howell M, Boguniewcz M, Yao L, et al. IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006;117:418-25.

5. Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involve- ment of TRPV1 and TRPA1. J Allergy Clin Immunol 2014;133:448-60.

6. Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018;73:29-36.

7. Cornelissen C, L€uscher-Firzlaff J, Baron JM, L€uscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol 2012;91:552-66.

8. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 2017;376:826-35.

9. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nem- olizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 2018;142:1121-30.e7.

10. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009;361: 2046-55.

11. Zhang Q, Davis JC, Dove CG, Su HC. Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome. Dis Markers 2010;29:131-9.

12. Yamamura K, Uruno T, Shiraishi A, Tanaka Y, Ushijima M, Nakahara T, et al. The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction. Nat Commun 2017;8:13946.

13. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11: 72-82.

14. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148:399-408.

15. Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia- inducible factors. Nature 2015;524:303-8.

16. Moreno-Manzano V, Rodr´ıguez-Jim´enez FJ, Ace~na-Bonilla JL, Fustero-Lard´ıes S, Erceg S, Dopazo J, et al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem 2010;285: 1333-42.

17. Smythies JA, Sun M, Masson N, Salama R, Simpson PD, Murray E, et al. Inherent DNA-binding specificities of the HIF-1a and HIF-2a transcription factors in chro- matin. EMBO Rep 2019;20:e46401.

18. Pawlus MR, Hu CJ. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal 2013;25:1895-903.

19. Mikulska JE. Analysis of response elements involved in the regulation of the hu- man neonatal Fc receptor gene (FCGRT). PLoS One 2015;10:e0135141.

20. Xu J, Zanvit P, Hu L, Tseng PY, Liu N, Wang F, et al. The cytokine TGF-b induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching. Immunity 2020;53:371-83.

21. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibi- tion as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843-62.

22. Peng T, Qi B, He J, Ke H, Shi J. Advances in the development of phosphodiesterase-4 inhibitors. J Med Chem 2020;63:10594-617.